Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.

OBJECTIVE: Evaluate safety, efficacy, and response markers to atezolizumab, an immune checkpoint inhibitor, when combined with neoadjuvant chemotherapy (NACT) for primary epithelial ovarian, tubal, and peritoneal cancer (EOC). METHODS: Eligible patients had high-grade stage III/IV EOC planned for NACT and interval cytoreductive surgery (ICS). After pretreatment biopsy, patients receivedweekly paclitaxel (80 mg/m2) with carboplatin (AUC6) and atezolizumab (1200mg) every 3 weeks for 3 cycles before ICS, and 3 cycles +/- bevacizumab post-ICS, followed by maintenance atezolizumab +/- bevacizumab or a PARPinhibitor. The primary endpoint was frequency of delay in ICS due to atezolizumab-related toxicities. Frequency/severity of adverse events (AE), response prior to ICS, and immune translational parameters were assessed. RESULTS: Negative results of IMagyn050 led to early termination; 18 of 40 planned patients enrolled: median age 69 years (range 46-87); majority were white (78%), had Stage III disease (72%), high-grade serous histology (100%), and no BRCAmutation (72%). Fifteen patients underwent ICS; 3 stopped protocol therapy prior to cycle 3 for non-atezolizumab-related reasons. Thromboembolism led to delay of ICS in one patient. Optimal cytoreduction was achieved in 13 (86%) patients. Treatment-related AEs were as expected. Partial response occurred in 9 (60%) and stable disease in 6 (40%). Patients with response versus stable disease had elevated post-treatment CXCL10, TNFα, and IL10. Immune compartments showed increased inflammatory markers, while tumor showed increased inflammatory and suppressive markers. CONCLUSIONS: NACT with atezolizumab was feasible and did not delay ICS. Translational parameters showed heterogeneous changes reflecting both immune activation and adaptive immune resistance.

Duke Scholars

Author Andrew Berchuck Obstetrics and Gynecology, Gynecologic Oncology

Author Angeles Alvarez Secord Obstetrics and Gynecology, Gynecologic Oncology

Author Stephanie Gaillard Medicine, Medical Oncology

Author Andrew Benjamin Nixon Medicine, Medical Oncology

Author Kouros Owzar Biostatistics & Bioinformatics, Division of Integrative Geno ...

Author John S Yi Surgery, Surgical Sciences

Author Brittany A Davidson Obstetrics and Gynecology, Gynecologic Oncology

Author Haley A Moss Obstetrics and Gynecology, Gynecologic Oncology

Author Jadee Lee Neff Pathology